Visit the original URL
According to the National Medical Insurance Administration, the 2022 National Medical Insurance Drug List negotiation work officially ended on January 8. The person in charge of the Pharmaceutical Management Department of the National Medical Security Administration introduced the situation of the participation of new crown therapeutic drugs in the negotiation of the medical insurance drug list. This year, a total of three COVID-19 treatment drugs, Azivudine Tablets, Naimatevir Tablets/Ritonavir Tablets Combination Packaging (hereinafter referred to as “Paxlovid”), and Qingfei Paidu Granules, have passed self-declaration, form review, expert review, etc. program, participated in the negotiations. Among them, Azivudine Tablets and Qingfei Paidu Granules were successfully negotiated, but Paxlovid failed due to the high quotation of the manufacturer Pfizer Investment Co., Ltd. (Beijing News)
media reports
Sina Titanium Media Sina 36Kr 36Kr
related events
- National Medical Insurance Administration: Paxlovid failed to be included in the medical insurance catalog through negotiation due to high quotation from Pfizer2023-01-08
- National medical insurance negotiations start, Pfizer’s new crown oral drugs, a variety of high-priced rare disease drugs face “soul bargaining” 2023-01-05
This article is transferred from: https://readhub.cn/topic/8mpB4BlQEar
This site is only for collection, and the copyright belongs to the original author.